In contrast, the pCR of patients with low TILs (0–10%) in TNBC and HER2+ BC was not as good as that of patients who manifested high TIL levels at diagnosis (22, 71), suggesting that treatment using these TILs may be an option for these patients. Here, ERBB2 is linked to breast cancer.